Loading...
•
Sep 30, 2025
OraSure Q3 2025 Earnings Report
OraSure reported its third quarter 2025 financial results, with total net revenues decreasing by 32% year-over-year to $27.1 million.
Key Takeaways
OraSure Technologies experienced a challenging third quarter in 2025, with total net revenues declining significantly by 32% to $27.1 million compared to the same period last year. This decline was primarily driven by decreases across its core business segments, including Diagnostics and Sample Management Solutions, as well as a near-complete cessation of COVID-19, Risk Assessment Testing, and Molecular Services revenues. Despite the downturn, the company remains optimistic about returning to growth in 2026 through diversification and new product launches, supported by a strong balance sheet.
Total net revenues for Q3 2025 decreased by 32% to $27.1 million from $39.9 million in Q3 2024.
Core revenues, excluding COVID-19, Molecular Services, and Risk Assessment Testing, decreased by 25% year-over-year to $27.0 million.
The company reported a GAAP net loss of $13.7 million and a Non-GAAP net loss of $9.8 million for the quarter.
OraSure maintains a strong cash position with $216.5 million in cash and cash equivalents as of September 30, 2025.
Revenue by Segment
Forward Guidance
OraSure Technologies is guiding for Q4 2025 total revenues to be between $25 million and $28 million, with COVID-19 testing revenues expected to be less than $100 thousand. The company anticipates a return to growth in 2026, driven by customer diversification and new product launches.
Positive Outlook
- Expected return to growth in 2026.
- Diversification of customer base.
- Planned launches of new products in rapid diagnostics and sample management solutions.
- Strong balance sheet provides flexibility to navigate short-term turbulence.
- Upcoming launch of Sherlock over-the-counter molecular self-test for Chlamydia and Gonorrhoeae and Colli-Pee urine self-collection for STIs.
Challenges Ahead
- Continued elevated levels of uncertainty related to funding for public health programs and research.
- Q4 2025 revenue guidance of $25 million to $28 million indicates ongoing revenue decline compared to previous periods.
- COVID-19 testing revenues are expected to be minimal (less than $100 thousand) in Q4 2025.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...